After FDA approved nirmatrelvir/ritonavir in December 2021 to be used for non-severe COVID-19 cases but in risk of progressing into severe disease, Malden et al. decided to evaluate its efficacy in lowering the risk of the concerned progression [56]. Therefore, they gathered the data of 52...
The FDA's approvedlabelfor Paxlovid is limited to treating infected "adults who are at high risk for progression to severe COVID-19." Doctors typically have the freedom to prescribe fully approved drugs"off-label"for other reasons to their patients, beyond the FDA's approval. ...
What to know about Pfizer's COVID-19 vaccine for kids 5 to 11 Kids between the ages of 5 and 11 are now eligible to get the Pfizer-BioNTech COVID-19 vaccine. WASHINGTON (AP) - Pfizer asked U.S. regulators Tuesday to authorize its experimental pill for COVID-19, setting the stage ...
While Paxlovid is authorized for use in adolescents and teenagers ages 12 and up, and weighing at least 88 pounds, that age group wasn’t tested in the original clinical trial. But because many children reach 88 pounds—considered to be an adult weight—the FDA has allowed extensions of EUA...
The FDA's approved label for Paxlovid is limited to treating infected "adults who are at high risk for progression to severe COVID-19." Doctors typically have the freedom to prescribe fully approved drugs "off-label" for other reasons to their patients, beyond the FDA's approval. But bec...